Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886782 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00886782 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 11 participants.
The verdict
NCT00886782, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.
Interventions
- DRUG Cdc7-inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-05-31 |
| Est. Completion | 2010-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00886782
The ClinicalTrials.gov registry entry for NCT00886782 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cdc7-inhibitor is the first listed.
NCT00886782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00886782 about?
NCT00886782 is a clinical study titled "A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors". The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.
What is the current status of trial NCT00886782?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-05-31. Estimated completion is 2010-08-04.
What interventions are being tested in trial NCT00886782?
The interventions under investigation include: Cdc7-inhibitor (DRUG).
Who is sponsoring clinical trial NCT00886782?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.